Login to Your Account



Clinic Roundup


Thursday, January 27, 2011
Photocure ASA, of Oslo, Norway, reported Phase II results showing that Cevira, a photodynamic therapy that combines a drug formulation and a medical device designed for the nonsurgical treatment of cervical human papillomavirus infection and precancerous lesions of the cervix, produced a three-month response rate of 71 percent in patients with mild cervical abnormalities vs. 43 percent in the control group.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription